EMA clears Oryzon to launch HOPE-2 Phase II vafidemstat trial in Phelan-McDermid syndrome
Bitget2026/09/28 06:26- EMA cleared Oryzon Genomics to start the Phase IIa HOPE-2 trial of vafidemstat in Phelan-McDermid syndrome.
- Open-label, single-center study targets 12 adults in Spain, with 12 weeks of dosing and an option to extend to 24 weeks.
- Trial is partly funded through Oryzon’s VANDAM project under the EU-backed Med4Cure IPCEI health program.
- Spain’s Ministry of Science, Innovation and Universities, CDTI, and the EU’s NextGenerationEU are providing the public funding.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Former Chainlink Product Marketing Director Michael Robinson joins Monad Foundation
The Federal Reserve Eyes $1.8 Trillion in “Shadow Credit”: Dallas and New York Fed Launch First Private Credit Survey
The Dallas and New York Federal Reserves have launched an investigation into private credit lending standards, covering an industry worth 1.8 trillions USD, with a minimum threshold of 50 millions USD. The results will be released in the first quarter of 2027.
Tom Lee Says a VIX Signal Points to a Stock Market Bottom
Is AI an engine or a killer? Morgan Stanley provides answers with data: productivity soars, but nearly 90% of the benefits are taken by 12 industries
Morgan Stanley stated that the productivity dividends from AI are concentrated in 12 highly exposed industries, with growth rates reaching twice the twenty-year average. For the first time, signs of job replacement have emerged.
Crypto prices
More
